Many of the severe cases of the currently spreading COVID-19 result from an over-reaction of the immune system. Exosomes derived from mesenchymal stem cells (MSCs) have the potential for an effective treatment of immune-mediated diseases, because they constitute the strong immunosuppressive effects of MSCs, while overcoming their limitations in availability, safety, and stability. In a prospective nonrandomized open-label study, Sengupta et al. explored the efficacy and safety of exosomes (ExoFlo™) derived from bone marrow MSCs in the treatment of severe COVID-19. They provided ExoFlo™ intravenously to 24 SARS-CoV-2 positive patients with severe symptoms. After the treatment, patient’s oxygenation and inflammatory markers improved significantly, while no adverse events occurred within the observation period. Although further randomized controlled trials are required, the possible application of exosomes as a therapeutic against severe COVID-19 seems encouraging.
Read more about our novel method for a quick and simple isolation of pure and functional exosomes here.
For detailed information read the full paper here.
Sengupta, Vikram & Sengupta, Sascha & Lazo, Jr & Woods, Peter & Nolan, Anna & Bremer, Nicholas. (2020). Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells and Development.